Table 5

GEE results (OR (95% CI)) for the outcomes erosion progression, joint space narrowing progression and Sharp–van der Heijde progression yes/no in the four treatment strategies

Erosion progressionJSN progressionSHS progression
Sequential monotherapy
 Swollen, ever3.0 (1.8 to 4.9)4.5 (2.5 to 8.0)2.9 (1.9 to 4.3)
 Tender, ever3.5 (1.9 to 6.7)2.2 (1.02 to 4.8)2.5 (1.4 to 4.3)
Step-up combination treatment
 Swollen, ever1.6 (0.9 to 3.1)1.7 (0.98 to 3.1)1.6 (1.0 to 2.5)
 Tender, ever2.7 (1.1 to 6.8)3.1 (1.5 to 6.5)2.9 (1.6 to 5.0)
Initial combination with prednisone
 Swollen, ever3.8 (1.5 to 9.4)2.9 (1.5 to 5.9)3.2 (1.7 to 6.3)
 Tender, ever1.8 (0.7 to 4.6)2.4 (1.2 to 5.1)2.1 (1.2 to 3.6)
Initial combination with infliximab
 Swollen, ever0.9 (0.4 to 2.0)1.2 (0.8 to 2.8)1.2 (0.7 to 2.1)
 Tender, ever1.4 (0.8 to 2.5)2.0 (0.8 to 4.9)2.0 (1.1 to 3.5)
  • All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression) JSN at baseline yes/no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), age, gender, body mass index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, double negative), treatment group and erythrocyte sedimentation rate.

  • CCP, cyclic citrullinated peptide; GEE, generalised estimating equations; JSN, joint space narrowing; SHS, Sharp–van der Heijde score.